When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Avaliable from: http://goldcopd.org/.Accessed January 2020.
   Google Scholar
• Lopez-CamposJL, Marquez-MartinE, Ortega-RuizF. Triple therapy vs. triple therapy in COPD. Arch Bronconeumol. 2017;53(8):419–420.28314634
   PubMed Web of Science ®Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.30232048
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnacleH, BirkR, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446.28375647
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.29668352
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.29429593
   PubMed Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.27598678
   PubMed Web of Science ®Google Scholar
• CalzettaL, RoglianiP, MateraMG, CazzolaM. A Systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196.26923629
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AnzuetoAR, CarterK, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344.29605624
   PubMed Web of Science ®Google Scholar
• MartinezFJ, VestboJ, AndersonJA, et al. Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction. Am J Respir Crit Care Med. 2017;195(7):881–888.27767328
   PubMed Web of Science ®Google Scholar
• CelliBR, WedzichaJA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–1266.31553837
   PubMed Web of Science ®Google Scholar
• BrusselleG, PriceD, Gruffydd-JonesK, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.26527869
   PubMed Web of Science ®Google Scholar
• CasanovaC, Aguirre-JaimeA, de TorresJP, et al. Longitudinal assessment in COPD patients: multidimensional variability and outcomes. Eur Respir J. 2014;43(3):745–753.24072210
   PubMed Web of Science ®Google Scholar
• JonesPW, AgustiAG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(4):822–832.16585091
   PubMed Web of Science ®Google Scholar
• HalpinDM, TashkinDP. Defining disease modification in chronic obstructive pulmonary disease. COPD. 2009;6(3):211–225.19811377
   PubMedGoogle Scholar
• MahlerDA, CrinerGJ. Assessment tools for chronic obstructive pulmonary disease: do newer metrics allow for disease modification? Proc Am Thorac Soc. 2007;4(7):507–511.17878462
   PubMedGoogle Scholar
• NayaIP, TombsL, MuellerovaH, ComptonC, JonesPW. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018;19(1):222.30453972
   PubMed Web of Science ®Google Scholar
• SinghD, CrinerGJ, NayaI, et al. Measuring disease activity in COPD: is clinically important deterioration the answer? Respir Res. 2020;21(1):134.32487202
   PubMed Web of Science ®Google Scholar
• SinghD, Maleki-YazdiMR, TombsL, IqbalA, FahyWA, NayaI. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424.27445468
   PubMed Web of Science ®Google Scholar
• NayaI, ComptonC, IsmailaAS, et al. Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Res. 2018;4:4.
   Google Scholar
• MaltaisF, BjermerL, KerwinEM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238.31666084
   PubMed Web of Science ®Google Scholar
• EjioforS, TurnerAM. Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med. 2013;7:17–34.23700381
   PubMedGoogle Scholar
• KaplanAG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:2535–2548.26648711
   PubMed Web of Science ®Google Scholar
• KewKM, SeniukovichA. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):CD010115.24615270
   PubMed Web of Science ®Google Scholar
• MorjariaJB, RigbyA, MoriceAH. Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT study. Lung. 2017;195(3):281–288.28255905
   PubMed Web of Science ®Google Scholar
• AgustiA, GeaJ, FanerR. Biomarkers, the control panel and personalized COPD medicine. Respirology. 2016;21(1):24–33.
   PubMed Web of Science ®Google Scholar
• SinghD, RocheN, HalpinD, AgustiA, WedzichaJA, MartinezFJ. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(5):541–549.27585383
   PubMed Web of Science ®Google Scholar
• GlaabT, VogelmeierC, BuhlR. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79.20565728
   PubMed Web of Science ®Google Scholar
• OgaT, TsukinoM, HajiroT, et al. Multidimensional analyses of long-term clinical courses of asthma and chronic obstructive pulmonary disease. Allergol Int. 2010;59(3):257–265.20657164
   PubMedGoogle Scholar
• CalverleyPM. Minimal clinically important difference–exacerbations of COPD. COPD. 2005;2(1):143–148.17136975
   PubMedGoogle Scholar
• JonesPW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79.17136966
   PubMedGoogle Scholar
• CalzettaL, CazzolaM, MateraMG, RoglianiP. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019;155(4):758–770.30660781
   PubMed Web of Science ®Google Scholar
• NayaIP, TombsL, LipsonDA, ComptonC. Preventing clinically important deterioration of COPD with addition of umeclidinium to Inhaled Corticosteroid/Long-Acting beta2-agonist therapy: an integrated post hoc analysis. Adv Ther. 2018;35(10):1626–1638.30191464
   PubMed Web of Science ®Google Scholar
• SinghD, FabbriLM, VezzoliS, PetruzzelliS, PapiA. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2019;14:531–546.30880943
   PubMed Web of Science ®Google Scholar
• PostmaDS, RabeKF. The Asthma-COPD Overlap Syndrome. N Engl J Med. 2015;373(13):1241–1249.26398072
   PubMed Web of Science ®Google Scholar
• VanfleterenL, UllmanA, NordensonA, AnderssonA, AndelidK, FabbriLM. Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. ERJ Open Res. 2019;5:1.
   Google Scholar